Abstract

Aim: Bakri Balloon is used in the treatment of postpartum hemorrhage (PPH) for conservative management of uterine bleeding. The aim of this study is to evaluate the results of using Bakri balloon in the treatment of PPH in a 5-year period in a tertiary hospital.

Material and Methods: Patients who underwent Bakri balloon for PPH treatment from October 2015 to December 2020 were retrospectively screened.

Results: The total number of deliveries were 17117, including 9595 vaginal (56%) and 7522 cesarean sections (44%). The Bakri balloon was applied to a total of 60 patients with a median age of 29 years; 20% of these patients were nullipara, 25% primiparous and 55% multiparous. The delivery method of 83.3% of the patients was cesarean section and vaginal delivery in 16.7% of the patients. A previous cesarean section history was present in 60% of the patients. While 47 patients were above the 34th gestational week, 13 patients were below the 34th gestational week. While 40 newborns were healthy, 2 newborns died and 18 were hospitalized in intensive care units. The cause of uterine hemorrhage was placenta previa in 29 patients and uterine atony in 28 patients. Bakri balloon treatment was sufficient in 91.7% of the patients, and no additional method was required. The Bakri balloon application failed in 5 patients (8.3%) and these patients underwent surgery.

Discussion: According to this study, the most common Bakri balloon indications were bleeding due to placenta previa and uterine atony. In these patients, treatment with Bakri Balloon was successful. In the treatment of PPH caused by placenta previa or uterine atony after both vaginal delivery or cesarean delivery, obstetricians can benefit from the cushioning effect of the Bakri balloon on the endometrial space to reduce or stop bleeding.

Keywords

Uterine hemorrhage; Uterine atony; Pregnancy complications
Introduction
Postpartum hemorrhage (PPH) is defined as a blood loss of 1,000 mL or more or signs and symptoms of hypovolemia within the first 24 hours after delivery and up to 12 weeks postpartum, regardless of method of delivery (vaginal or cesarean) [1]. Early or primary PPH, the most common type occurs within the first 24 hours of delivery. PPH is the cause of approximately 35% of all maternal deaths. In the developing world, about 1.2% of deliveries are associated with PPH, and when PPH occurred, about 3% of women died [2]. Most research on PPH has focused on the PPH prevention. Although controversy continues regarding the optimal protocol for PPH prevention, the use of oxytocin is currently preferred. Misoprostol may be a reasonable option when parenteral administration of uterotonic is not possible [3]. There is little evidence to guide treatment decisions when PPH occurs [4]. Pharmacological, mechanical, and surgical methods to treat PPH are mentioned in many publications [5]. Many reports recommend uterine massage and bladder emptying to induce uterine contractions as first-line therapy [6]. Surgical options are usually laparotomy to apply compression sutures, bilateral uterine and/or hypogastric artery ligation, hysterectomy (total or subtotal) or Pelvic tamponade (abdominal packing) [6-8].
In recent years, many studies have referred to intravascular balloon tamponade as a second-line therapy, before resorting to emergency peripartum hysterectomy in cases with PPH and uterotic treatment failure [9-12]. The Bakri balloon is the first specifically designed for the uterus cavity [13].
In this study, the 5-year Bakri balloon experience in a maternity hospital was reviewed. General characteristics of the patients who underwent Bacri balloon indication, whether the procedure was successful, and the condition of the newborn were analyzed.

Material and Methods
Local ethics committee approval was obtained for this study (Date: February 5, 2021 Number: 2709). In this study, patients with Bakri balloon records for the last 5 years (from October 1, 2015, to December 30, 2020) were scanned from the hospital pharmacy. Since the Bakri balloon is a high-cost device, the insurance system requires an official report, which is recorded in the hospital pharmacy. Patients were found from these records, and then the files of these patients were collected from the hospital archive. The age, gravida, parity, delivery method, gestational week of these patients were found in the patient file. The cause of postpartum bleeding, the condition of the newborn, and whether the Bakri balloon application was successful or not, were recorded in excel format.

Patient selection
As a clinical approach, in the maternity ward, patients are taken to the follow-up room after birth (cesarean or vaginal delivery) where blood pressure, pulse, vaginal bleeding and hemogram are closely monitored. According to this monitoring by the service nurse, the delivery team is informed when PPH is detected. Patients diagnosed with PPH are applied uterine massage and medical treatment (oxitocin and misoprostol) as first-line therapy. Among the patients who did not respond to this treatment, Bakri Balon implanted patients were included in the study. The entire study group consists of patients who failed this first-line treatment. The Bakri balloon was inserted during cesarean section in cases of bleeding during cesarean section (especially in patients with placenta previa) and continuing bleeding despite sufficient suturing in the uterine bed. The Bakri balloon was inflated to an average of 300 to 500 cc. Patients who underwent laparotomy directly for hysterectomy or uterine artery ligation without applying Bakri balloon were excluded from the study.

Results
The total number of deliveries was 17117, including 9595 vaginal (56%) and 7522 cesarean sections (44%). The Bakri balloon was applied in a total of 60 patients with a median age of 29 (14-42) years (Table 1); 20% (n=12) of these patients were nullipara, 25% (n=15) primiparous and 55% (n=33) multiparous. In terms of delivery method, 85.3% (n = 50) of the patients had a cesarean section and 16.7% (n = 10) had a vaginal delivery. 60% (n = 36) of the patients had a previous cesarean section history. While 47 patients (78.3%) were above the 34th gestational week, 13 patients (21.7%) were below the 34th gestational week. While 40 newborns (66.7%) were healthy, 2 newborns died and 18 received intensive care treatment. In the study group, 2 patients had twin pregnancy and the rest had single pregnancy. The cause of uterine hemorrhage was placenta previa in 29 patients (48.4%) and uterine atony in 28 patients.

Table 1. Data of 60 patients with Bakri balloon applied

| Feature | Value |
|---------|-------|
| Age, median (min-max)(25%-75% percent) | 29(14-42)(24.2-35.7) |
| Pariety, n % | |
| Nullipar | 12 (20%) |
| Primipar | 15 (25%) |
| Multipar | 33 (55%) |
| Delivery method, n % | |
| Cesarean | 50 (83.3%) |
| Vaginal delivery | 10 (16.7%) |
| Gestational week at birth | |
| < 30 | 3 (5.0%) |
| 30-34 | 10 (16.7%) |
| 35-38 | 31 (51.6%) |
| >38 | 16 (26.7%) |
| Twin pregnancy, n % | 2 (3.3%) |
| Cause of postpartum hemorrhage, n % | |
| Placenta previa | 29 (48.4%) |
| Atony | 28 (46.7%) |
| Placenta accreta | 2 (3.4%) |
| Placental detachment | 1 (1.7%) |
| Newborn outcomes | |
| Healthy | 40 (66.7%) |
| Intensive care | 18 (30.0%) |
| Exitus | 2 (3.4%) |
| Bakri balloon treatment | |
| Successful | 55 (91.7) |
| Laparotomy requirement | 5 (8.3%) |
| Hysterectomy | 3 (5.1%) |
| Hypogastric artery ligation (HAL) | 1 (1.7%) |
| HAl plus Recurrent Bacri | 1 (1.7%) |
patients (46.7%). Two patients (3.4%) were diagnosed with placenta accreta and one patient (1.7%) was diagnosed with ablatio placenta and Bakri balloons were applied. Bakri balloon treatment was sufficient in 91.7% of the patients, and no additional method was required. The Bakri balloon application failed in 5 patients (8.3%), and these patients underwent surgery. Postpartum hysterectomy was applied to three of these patients, hypogastric artery ligation to one and hypogastric artery ligation plus recurrent Bacri balloon to one.

Discussion

In this study, the results of patients who were unresponsive to first-line treatment (oxitocin, misoprostol and uterine massage) for PPH and who were applied Bakri balloon were reviewed. The purpose of Bakri balloon application is to treat uterine bleeding, provided that laparotomy and possible hysterectomy are avoided. The success of the Bakri balloon can be mentioned in patients who have achieved PPH treatment without the need for surgical approach. In our study consisting of 60 patients, we saw that the Bakri balloon was successful in 55 patients (91.7%). According to the results of this study, Bakri balloon seems to be quite effective. We think that patient selection has a critical role in this. We saw that the number of patients with insertion anomalies such as placenta accreta, increta or percreata was low in the study population (2 patients). This approach may be effective in the emergence of this high rate. The predominant group (95.1%) of the study was patients with uterine atony or placenta previa.

Postpartum hemorrhage continues to be a gross cause of maternal deaths [2]. Timely and appropriate approach plays a critical role in preventing maternal death. There are many publications in the literature on the place of the Bakri balloon at PPH, and a consensus seems to have been occurred for the Bakri balloon with meta-analyses and systematic reviews in recent years [14-16].

Application of Bakri balloon instead of uterine-sparing surgical approaches (uterine/hypogastric artery ligation, B-lynch suture) is more advantageous to prevent the morbidity of the surgery. In this topic, Ramler et al. in their study, compared uterine artery embolization and uterine balloon tamponade in 100 patients with postpartum hemorrhage and stated that no difference in the risk of peripartum hysterectomy and/or maternal death was observed between women who had intrauterine balloon tamponade and women who underwent uterine artery embolization as initial management for persistent postpartum hemorrhage [9]. In another study, Kaya et al. found that the Bakri balloon and B-Lynch suture had similar success rates in uterine atony during cesarean section [11]. Grange et al. found 74.1% Bakri balloon success for persistent PPH in their study and stated that Bakri balloon is an effective second-line treatment for persistent primary PPH. In their study, they found that pre-pregnancy obesity was a risk factor for Bakri balloon failure [17]. Cho et al. used a Bakri balloon during cesarean section due to postpartum bleeding from the lower uterine segment and they found that Bakri balloon was successful in 75% of the patients and stated that Bakri balloon is an adequate adjunct management for postpartum hemorrhage following cesarean section for placenta previa to preserve the uterus [18].

This study has limitations such as being retrospective, partially a small number of patients, and lack of some data. If it was recorded how many cc of Bakri balloon was inflated for each patient, more useful results could be obtained. In conclusion, intrauterine tamponade with a Bakri balloon can be considered as an option before the surgical approach, especially in patients with PPH due to uterine atony or placenta previa who do not respond to first-line therapy such as uterine massage, oxytocin and misoprostol. Identifying the group with the high probability of failure of the Bakri balloon also plays a critical role.

Scientific Responsibility Statement

The authors declare that they are responsible for the article's scientific content including study design, data collection, analysis and interpretation, writing, some of the main line, or all of the preparation and scientific review of the contents and approval of the final version of the article.

Animal and human rights statement

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. No animal or human studies were carried out by the authors for this article.

Funding: None

Conflict of interest

None of the authors received any type of financial support that could be considered potential conflict of interest regarding the manuscript or its submission.

References

1. American College of Obstetricians and Gynecologists. Practice Bulletin No. 183: postpartum hemorrhage. Obstet Gynecol. 2017;130(4):e168-86.
2. Weeks A. The prevention and treatment of postpartum haemorrhage: what do we know, and where do we go next? BJOG. 2015;122(2):202-10.
3. World Health Organization. WHO recommendations for the prevention and treatment of postpartum haemorrhage. Geneva: WHO, 2012.
4. Rajaan PV, Wing DA. Postpartum hemorrhage: evidence-based medical interventions for prevention and treatment. Clin Obstet Gynecol. 2010;53(1):165-8.
5. Muriaz M, Sorsballe J, Ducloy-Bouthors AS, Bonnet M-P, De Robertis E, Fornet I, et al. Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement. Blood Transfus. 2019;17(2):112-36.
6. Prevention and Management of Postpartum Haemorrhage: Green-top Guideline No. 52. BJOG. 2017;124(5):e106-e49.
7. Likis FE, Sathe NA, Morgans AK, Hartmann KE, Young JL, Carlson-Bremer D, et al. Management of postpartum hemorrhage. AHRQ Comparative Effectiveness Reviews. Rockville, MD, USA, Agency for Healthcare Research and Quality (US); 2015.
8. Defieux X, Vichaint M, Wigniolle I, Gaffinet F, Sentilhes L. Maternal outcome after abdominal packing for uncontrolled postpartum hemorrhage despite peripartum hysterectomy. PLoS One. 2017;12(6):e0177092.
9. Ramler P, Henriquez DDCA, van den Akker T Comparison of outcome between intrauterine balloon tamponade and uterine artery embolization in the management of persistent postpartum hemorrhage: A propensity score-matched cohort study. Acta Obstet Gynecol Scand. 2019;98(11):1473-82.
10. Matsubara S, Tokashhi N, Lefor AK. Intrauterine hemostatic balloon placement: is <12 hours really better? Am J Obstet Gynecol. 2017;216(5):537-8.
11. Kaya B, Guralp O, Tuten A, Unal O, Celik MO, Dogan A. Which uterine sparing technique should be used for uterine atony during cesarean section? The Bakri balloon or the B-Lynch suture? Arch Gynecol Obstet. 2016;294(3):511-7.
12. Nagai S, Kobayashi H, Nagata T, Hiwataishi S, Kawamura T, Yokomine D, et al. Clinical Usefulness of Bakri Balloon Tamponade in the Treatment of Massive Postpartum Uterine Hemorrhage. Kurume Med J. 2016;62(1-2):17-21.
13. Raynal P, Le ballonnet de Bakri [Bakri balloon]. Gynecol Obstet Fertil. 2011;39(7-8):438-41.
14. Suarez S, Conde-Agudelo A, Borovac-Pinheiro A, Suarez-Rebling D, Eckardt M, Theron G, et al. Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic review and meta-analysis. Am J Obstet Gynecol. 2020;222(4):293.
15. Anukumar S, Fuchten C. Uterine balloon tamponade for the treatment of postpartum hemorrhage: a systematic review and meta-analysis-commentary. Am J Obstet Gynecol. 2020;222(4):291-2.
16. Said Ali A, Faroq E, Mohammad M. The safety and effectiveness of Bakri balloon in the management of postpartum hemorrhage: a systematic review.
Bakri balloon in postpartum hemorrhage

Matern Fetal Neonatal Med. 2021;34(2):300-7.
17. Grange J, Chatellier M, Chevé MT, Paumier A, Launay-Bourillon C, Legendre G, et al. Predictors of failed intrauterine balloon tamponade for persistent postpartum hemorrhage after vaginal delivery. PLoS One. 2018;13(10).
18. Cho HY, Park YW, Kim YH, Jung I, Kwon JY. Efficacy of Intrauterine Bakri Balloon Tamponade in Cesarean Section for Placenta Previa Patients. PLoS One. 2015;10(8).

How to cite this article:
Işık Kaban, Besim Haluk Bacanakgil. Bakri balloon in the treatment of postpartum hemorrhage. Ann Clin Anal Med 2021;12(4):462–465